长春高新：12月15日召开董事会会议

Group 1 - The core viewpoint of the article is that Changchun High-tech (SZ 000661) held its 15th meeting of the 11th Board of Directors on December 15, 2025, to review the proposal for signing an exclusive licensing agreement for the GenSci098 injection project [1] - For the first half of 2025, the revenue composition of Changchun High-tech is as follows: 92.83% from the pharmaceutical industry, 6.81% from real estate, and 0.36% from the service industry [1] - As of the time of reporting, the market capitalization of Changchun High-tech is 37.6 billion yuan [1]